Kiniksa Pharmaceuticals International, plc - 8-K Filing

Kiniksa Pharmaceuticals raises 2026 ARCALYST revenue guidance to $1.045B-$1.050B following Q3 revenue growth of 58% YoY. (Items: 2.02 Results of Operations and Financial ConditionOn October 27, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announci, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 27, 2026, 11:33 UTC

Tickers: $KNSA

Read the full article at SEC EDGAR

More Regulatory news

Newton Golf Company, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:14 UTC
XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC